| Description |
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research[1][2].
|
| Related Catalog |
|
| Target |
CD40[1]
|
| In Vitro |
Lucatumumab (0.001-10 μg/mL; 4 h; 37 ℃) inhibit B-cell chronic lymphocytic leukemia (B-CLL) growth by ADCC-mediated cell lysis, with the average maximal lysis of B-CLL cells of 49%[1]. Lucatumumab (0.1-10 μg/mL; 3 d) inhibits CD40L-induced signaling and viability of B-CLL cells[1]. Lucatumumab (10 μg/mL; 24 h) inhibits cytokine secretion by B-CLL cells[1]. Cell Viability Assay[1] Cell Line: B-cell chronic lymphocytic leukemia (B-CLL) Concentration: 0.001 to 10 μg/mL Incubation Time: 72 hours; 37 ℃ Result: Inhibited B-CLL growth with an ED50 of 14 pM and a average maximal lysis of B-CLL cells of 49%.
|
| References |
[1]. Luqman M, et al. The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood. 2008 Aug 1;112(3):711-20. [2]. Drgona L, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S83-S94.
|
